Pracytarabine

普瑞拉滨

Report date: 2026/02/05 17:27:48
NME

Base Information

Drug NamePracytarabine
Drug Alias NameMB-7133MB-07133MB-01733
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA-directed DNA polymerase inhibitors
TargetsDNA-directed DNA polymerase
Therapy Area/IndicationsMitochondrial DiseasesLiver NeoplasmsCholangiocarcinoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanHong Kong +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesLigand Pharmaceuticals Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesChiva Pharmaceuticals IncXi'an Xintong Pharmaceutical Research Co Ltd
Inactive CompaniesLigand Pharmaceuticals Inc
Active IndicationsMitochondrial DiseasesLiver NeoplasmsCarcinoma, Hepatocellular
Inactive IndicationsCholangiocarcinoma

Other Information

ATC CodeN/A
Related LinksN/A